X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Stemedica plans to initiate a Phase IIb/III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of a single intravenous injection of allogeneic adult mesenchymal bone marrow stem cell to subjects with ischemic stroke.
Lead Product(s): Allogeneic Adult Mesenchymal Bone Marrow Stem Cell
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
Prior to submission of an IND, fourteen critically ill COVID-19 patients were treated on Emergency Use and Expanded Use INDs. The stem cell treatment resulted in an improved clinical course for the patients within 24-48 hours of receiving the therapy.
Lead Product(s): Ischemic-tolerant mesenchymal stem cells
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2020
Details:
This IND application for emergency use was supported by pre-clinical data in an acute respiratory distress syndrome (ARDS) model.
Lead Product(s): Ischemic-tolerant mesenchymal stem cells
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
